Earnings Call · Q2 FY2025·2025-08-07

Q2 25EPS +100.00%*·Rev n/aQ1 25EPS +100.00%*·Rev n/aQ4 24EPS -33.33%·Rev n/aQ3 24EPS -100.00%·Rev n/a⚠ consensus missing

Akebia Therapeutics, Inc. AKBA

Mercedes Carrasco — Senior Director of Investor Relations

John P. Butler — Chief Executive Officer

Nicholas Grund — Chief Commercial Officer

Erik John Ostrowski — Chief Financial Officer

−20.5%1d on move date−20.4% vs SPY3d−11.5%5d−12.8%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more AKBA calls or request research access.

More AKBA calls Browse calls Request research access